Blog
RSS FeedPosted by Michael Wonder on 01 May 2025
AstraZeneca Korea reapplies for Lynparza reimbursement in prostate cancer
22 April 2025 - AstraZeneca Korea has recently reapplied for health insurance coverage for its PARP inhibitor Lynparza (olaparib) for ...
Posted by Michael Wonder on 16 Apr 2025
Merck’s Tepmetko wins reimbursement in Korea after 3.5 years, expanding access for lung cancer patients with rare MET mutation
15 April 2025 - Merck’s targeted lung cancer therapy Tepmetko (tepotinib) has finally secured reimbursement from the National Health Insurance ...
Posted by Michael Wonder on 10 Apr 2025
Pfizer wins Korea nod for paediatric arthritis use of oral JAK inhibitor Xeljanz
7 April 2025 - Pfizer Korea has won national reimbursement for its oral JAK inhibitor Xeljanz (tofacitinib), expanding access to ...
Posted by Michael Wonder on 04 Apr 2025
Janssen Korea’s Zytiga secures expanded reimbursement for first-line prostate cancer treatment
2 April 2025 - Beginning in April, Janssen Korea's prostate cancer drug Zytiga will be available with prednisolone as a ...
Posted by Michael Wonder on 03 Apr 2025
GSK Korea's long-acting HIV injection therapy gains insurance benefit
1 April 2025 - GSK Korea said its long-acting injectable HIV-1 combination treatment, Vocabria (cabotegravir 600 mg) and Rekambys (rilpivirine ...
Posted by Michael Wonder on 02 Apr 2025
Sanofi launches new cholesterol lowering injection in Korea with health insurance coverage
1 April 2025 - Sanofi Korea announced the launch of Praluent Pen 300 mg (alirocumab) today following its inclusion in ...
Posted by Michael Wonder on 20 Mar 2025
Global pharma gives up reimbursement in Korea, and this is a serious concern
19 March 2025 - "We believe convincing our headquarters is no longer feasible, and we have no plans to apply ...
Posted by Michael Wonder on 09 Mar 2025
Expanded reimbursement for Rinvoq enhances atopic dermatitis treatment options
7 March 2025 - Korean patients with moderate to severe atopic dermatitis now have greater flexibility in treatment as reimbursement ...
Posted by Michael Wonder on 04 Mar 2025
Roche Korea’s multiple sclerosis drug scores reimbursement
4 March 2025 - Roche Korea said its multiple sclerosis treatment, Ocrevus (ocrelizumab), started receiving reimbursement from last Saturday. ...
Posted by Michael Wonder on 03 Mar 2025
Amyloid cardiomyopathy drug Vyndamax to get health insurance from March
28 February 2025 - Vyndamax (tafamidis), a transthyretin amyloid cardiomyopathy medicine that has experienced difficulties getting on the health insurance ...
Posted by Michael Wonder on 23 Feb 2025
HIRA to remove 17 medicines from group 2 anti-cancer list, update reimbursement criteria
21 February 2025 - Korea's HIRA said it has decided to remove 17 medicines from the list of group 2 ...
Posted by Michael Wonder on 20 Feb 2025
Korea to implement new drug pricing policy that rewards innovation
20 February 2025 - The Ministry of Health and Welfare on Thursday announced a significant policy change in pharmaceutical pricing ...
Posted by Michael Wonder on 13 Feb 2025
Keytruda gets expanded coverage for 11 indications at cancer disease panel
13 February 2025 - After nearly two years of stalled discussions, the Keytruda (pembrolizumab) reimbursement expansion debate has finally begun. ...
Posted by Michael Wonder on 11 Feb 2025
Gilead’s breast cancer treatment Trodelvy passes drug reimbursement panel
7 February 2025 - Gilead's triple negative breast cancer treatment Trodelvy (trastuzumab govitecan) had surmounted a significant hurdle for health ...
Posted by Michael Wonder on 01 Feb 2025
Boehringer Ingelheim’s Jardiance gets expanded coverage for HFpEF patients
31 January 2025 - Boehringer Ingelheim Korea said that Jardiance (empagliflozin) 10 mg tablet, its sodium-glucose co-transporter-2 inhibitor, received expanded ...